Healthy volunteers help Fine-Tune Long-Acting HIV prevention drug
NCT ID NCT06033547
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This early-stage study tested two different versions of a long-acting HIV drug called cabotegravir in 56 healthy adults. The goal was to see how safe the drugs are and how they behave in the body over time. Participants received a single injection and were monitored for side effects and drug levels in the blood. This research helps improve future HIV prevention options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Austin, Texas, 78744, United States
Conditions
Explore the condition pages connected to this study.